IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
About IMAC Holdings, Inc.
- NASDAQ: $IMAC
- Notified: $1.84
- 11:58 EDT